MHRA streamlines approval process for established medicines
2024-02-29
Preview
来源: Pharmaceutical Technology
The latest process changes for established medicines are designed to streamline approvals and ensure efficient assessment. Credit: BigKhem / Shutterstock.com.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced process changes in its latest guidance aimed at enhancing the efficiency of assessing established therapies.
Set to come into effect on 1 March 2024, the guidance incorporates these changes to streamline the approvals process for applicants.
The new guidance stipulates that the regulator will not process incomplete applications. One request for further information will be provided, and on receipt of approval, applicants file a pre-populated summary template for the UK public assessment report.
Central to the new guidance is the introduction of a technical completeness check to ensure the MHRA has all necessary information at the outset of its review.
The initiative builds upon other measures the MHRA has implemented to enhance the submission process.
See Also:Beyond approval: Patients pursue alternate paths to get rare disease treatments
Preview
来源: Pharmaceutical Technology
The importance of high-quality raw materials in the development of Regenerative Medicine
Preview
来源: Pharmaceutical Technology
Applications filed before 1 January 2024 and pending first assessment can opt to convert to the agency’s new Mutual Recognition and Decentralised Reliance Procedure or the European Commission Decision Reliance Procedure.
The MHRA has also taken proactive steps to assist applicants in submitting complete applications, thereby reducing common deficiencies.
It emphasises the critical nature of timely processing for marketing authorisation applications of established medicines, which include products that are neither new active substances nor line extensions of new active substances.
The process change is specific to chemical products and does not apply to biosimilars.
The MHRA’s recent measures have already led to significant improvements in the processing of applications. The agency is committed to maintaining transparency by providing monthly updates on expected timescales for applicants.
The MHRA recently revoked a conditional marketing authorisation for Novartis’ Adakveo 10mg/ml concentrate for solution for infusion for the treatment of sickle cell disease.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。